Eosinophilic fasciitis: a modern view of diagnosis and treatment
DOI: 10.32364/2587-6821-2022-6-3-153-158
A.A. Akimova, M.A. Travin, E.A. Letyagina, M.A. Korolev
Research Institute of Clinical and Experimental Lymphology, the branch of the Research Center of Cytology and Genetics, the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation
Eosinophilic fasciitis is a systemic disease of the scleroderma group, characterized by skin and fascia induration of the upper and lower extremities, less commonly — of the trunk. The disease was first described by L.E. Shulman in 1974. The rare occurrence and literature description of this pathology do not present enough data for a clear understanding of the disease and clarification of epidemiological data. Clinical and morphological picture of the disease onset is very similar to the skin manifestations in systemic scleroderma (and it takes a long time for the development of organ lesions), so it complicates the diagnosis establishment. Each case described is very valuable. The article presents a clinical case of diagnosis verification concerning eosinophilic fasciitis in a 46-year-old male patient with clinical manifestations as skin induration of the extremities, hypereosinophilia of the blood and nonspecific inflammatory markers. The following instrumental techniques were used in the diagnosis: magnetic resonance imaging, ultrasound, biopsy. To relieve inflammation, the patient was prescribed glucocorticoids and cytostatics. Positive tendency was noted during the treatment. The presented case demonstrates the possibilities concerning the dynamic control of the disease course using ultrasound.
Keywords: eosinophilic fasciitis, scleroderma, ultrasound, biopsy, case report, methotrexate.
For citation: Akimova A.A., Travin M.A., Letyagina E.A., Korolev M.A. Eosinophilic fasciitis: a modern view of diagnosis and treatment. Russian Medical Inquiry. 2022;6(3):153–158 (in Russ.). DOI: 10.32364/2587-6821-2022-6-3-153-158.
About the authors:
Anna A. Akimova — rheumatologist of the Department of Rheumatology, Junior Research Fellow of the Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology, the branch of the Research Center of Cytology and Genetics, the Siberian Branch
of the Russian Academy of Sciences; 2, Timakov str., Novosibirsk, 630060, Russian Federation; ORCID iD 0000-0003-1099-3256.
Mikhail A. Travin — C. Sc. (Med.), forensic pathologist, Head of the Laboratory of Functional Morphology of the Lymphatic System, Research Institute of Clinical and Experimental Lymphology, the branch of the Research Center of Cytology and Genetics, the Siberian Branch of the Russian Academy of Sciences; 2, Timakov str., Novosibirsk, 630060, Russian Federation; ORCID iD 0000-0001-
6385-5784.
Elena A. Letyagina — C. Sc. (Med.), Head of the Rheumatology Department, Senior Researcher of the Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology, the branch of the Research Center of Cytology and Genetics, the Siberian Branch
of the Russian Academy of Sciences; 2, Timakov str., Novosibirsk, 630060, Russian Federation; ORCID iD 0000-0002-6275-2924.
Maxim A. Korolev — C. Sc. (Med.), Deputy Head of the Research Institute of Clinical and Experimental Lymphology, the branch of the Research Center of Cytology and Genetics, the Siberian Branch of the Russian Academy of Sciences; 2, Timakov str., Novosibirsk, 630060, Russian Federation; ORCID iD 000-0002-4890-0847.
Contact information: Anna A. Akimova, e-mail:
anya-zemtsova@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 19.01.2022.
Revised 11.02.2022.
Accepted 11.03.2022.
2. Алексейчик С.Е., Бизюк Л.А. Дифференциальная диагностика эозинофилии. Лечебное дело. 2010;2(12):65–79. [Aleksejchik S.E., Bizyuk L.A. Differential diagnosis of eosinophilia. Lechebnoe delo. 2010;2(12):65–79 (in Russ.)].
3. Ihn H. Eosinophilic fasciitis: From pathophysiology to treatment. Allergol Int. 2019;68(4):437–439. DOI: 10.1016/j.alit.2019.03.001.
4. Mazori D.R., Femia A.N., Vleugels R.A. Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment. Curr Rheumatol Rep. 2017;19(12):74. DOI: 10.1007/s11926-017-0700-6.
5. Jinnin M., Yamamoto T., Asano Y. et al. Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. J Dermatol. 2018;45(8):881–890. DOI: 10.1111/1346-8138.14160.
6. Londoño Correa A., Londoño Á., Ruiz A.C., Mesa M. Fascitis eosinofílica: reporte de un caso. Revista Colombiana de Reumatología. 2018;25(1):63–68. DOI: 10.1016/j.rcreu.2017.03.001.
7. Moulton S.J., Kransdorf M.J., Ginsburg W.W. et al. Eosinophilic fasciitis: spectrum of MRI findings. AJR Am J Roentgenol. 2005;184(3):975–978. DOI: 10.2214/ajr.184.3.01840975.
8. Kim H.J., Lee S.W., Kim G.J., Lee J.H. Usefulness of FDG PET/CT in the diagnosis of eosinophilic fasciitis. Clin Nucl Med. 2014;39(9):801–802. DOI: 10.1097/RLU.0000000000000260.
9. Verenes M., Stone S.L., Hobson-Webb L.D. et al. Neuromuscular ultrasound findings in eosinophilic fasciitis: A case series and literature review. Muscle Nerve. 2018;58(2):E15–E18. DOI: 10.1002/mus.26150.
10. Akesson A., Hesselstrand R., Scheja A., Wildt M. Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis. Ann Rheum Dis. 2004;63(7):791–796. DOI: 10.1136/ard.2003.012146.
11. Lamback E.B., Resende F.S., Lenzi T.C. Eosinophilic fasciitis. An Bras Dermatol. 2016;91(5 suppl 1):57–59. DOI: 10.1590/abd1806-4841.20164683.
12. Bukiej A., Dropiński J., Dyduch G., Szczeklik A. Eosinophilic fasciitis successfully treated with cyclosporine. Clin Rheumatol. 2005;24(6):634–636. DOI: 10.1007/s10067-005-1099-4.
13. Nahhas A.F., Alam M., Lim H.W. Rituximab as a therapeutic consideration for refractory eosinophilic fasciitis. Int J Dermatol. 2018;57(5):614–615. DOI: 10.1111/ijd.13940.
14. Kim S.R., Charos A., Damsky W. et al. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep. 2018;4(5):443–445. DOI: 10.1016/j.jdcr.2017.12.003.
15. Tkachenko E., Steuer A.B., Lo K. et al. Mycophenolate Mofetil for Eosinophilic Fasciitis: A Retrospective Analysis From 3 Tertiary Care Centers. JAMA Dermatol. 2020;156(5):595–597. DOI: 10.1001/jamadermatol.2020.0120.
16. Romano C., Rubegni P., De Aloe G. et al. Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol. 2003;17(1):10–13. DOI: 10.1046/j.1468-3083.2003.00587.x.
17. Kowal-Bielecka O., Fransen J., Avouac J. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. DOI: 10.1136/annrheumdis-2016-209909.
18. Насонов Е.Л. 50 лет применения метотрексата в ревматологии. РМЖ. 2000;9:372–376. [Nasonov E.L. 50 years of methotrexate use in rheumatology. RMJ. 2000;9:372–376 (in Russ.)].
19. Громов А.И., Буйлов В.М. Лучевая диагностика и терапия в урологии: национальное руководство. М.: ГЭОТАР-Медиа; 2011. [Gromov A.I., Builov V.M. Radiation diagnostics and therapy in urology. М.: GEOTAR-Media; 2011 (in Russ.)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
